![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NEUROLOGIX SIGNS PACT WITH DIAMYD SUBSIDIARY ON PARKINSON'S THERAPY
NEUROLOGIX SIGNS PACT WITH DIAMYD SUBSIDIARY ON PARKINSON'S THERAPY
August 10, 2006
Neurologix, Inc.,
a biotech company committed to developing innovative gene therapies for the brain
and central nervous systems, has entered into a licensing agreement with a subsidiary
of Diamyd Medical, a biotechnology company based in Stockholm, Sweden, and Pittsburgh,
PA.
Pharmabiz
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct